<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04051970</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 173</org_study_id>
    <nct_id>NCT04051970</nct_id>
  </id_info>
  <brief_title>Reducing Antiretroviral Treatments</brief_title>
  <acronym>ALTAR</acronym>
  <official_title>Randomized, Open-label, Phase III Trial Comparing a Dual Nucleoside Analogues Strategy Preceded by a Triple Therapy Induction Period to an Immediate Strategy With Dolutegravir Plus Lamivudine in Antiretriviral naïve People Living With HIV With Viral Load &lt; 50000 cp/mL and CD4 Cells &gt;300/mm3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to demonstrate at W48 the non-inferiority of a dual nucleoside
      analogues strategy with tenofovir (TDF) or tenofovir alafenamide (TAF) plus emtricitabine
      (FTC) or lamivudine (3TC) preceded by a 16 week induction period with TDF or TAF plus FTC or
      3TC plus an integrase inhibitor (INI) relative to an immediate 2-DR strategy with
      dolutegravir plus 3TC in HIV-infected antiretroviral therapy (ARV) naïve participants with
      CD4 cells count greater than 300/mm3 and a low viral load defined as plasma HIV RNA strictly
      lower than 50 000 cp/mL
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ANRS 173 ALTAR is a multicenter, comparative, international, open label, phase III randomized
      trial aiming at evaluating the non-inferiority of a TRI-BI (tritherapy-bitherapy) strategy
      (includes a 16 week - induction phase with 2 NRTI and a once daily integrase inhibitor
      followed by a bitherapy with TDF or TAF / XTC*) in its capacity to achieve viral suppression
      at week 48 versus immediate BI (bitherapy) strategy (DTG/3TC) in participants naïve to
      antiretroviral therapy with plasma HIV RNA strictly less than 50 000 copies/mL and CD4 cells
      count above 300/mm3.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate at W48 the non-inferiority</measure>
    <time_frame>proportion of participants with plasma HIV-RNA &lt;50 copies/mL at Week 48 in the 2 arms on allocated treatment (FDA snapshot approach)</time_frame>
    <description>To demonstrate at W48 the non-inferiority of a dual nucleoside analogues strategy with tenofovir (TDF) or tenofovir alafenamide (TAF) plus emtricitabine (FTC) or lamivudine (3TC) preceded by a induction period with TDF or TAF plus FTC or 3TC plus an integrase inhibitor (INI) relative to an immediate 2-DR strategy with dolutegravir plus 3TC in HIV-infected ART naïve participants with CD4 cells count greater than 300/mm3 and a low viral load defined as plasma HIV RNA strictly lower than 50 000 cp/mL</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Strategy TRI-BI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Strategy Immediate BI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiretroviral</intervention_name>
    <description>Antiretroviral treatments (ART) will be allocated through central randomization (1:1:) according to the following two strategies:
Tritherapy-Bitherapy (TRI-BI) strategy:
TRI between D0 and W16: 3-drug combination (3-DR) including 2 NRTI (either TDF or TAF+XTC) and a once daily integrase inhibitor (Stribild® or Genvoya® or Biktarvy®) or TDF/XTC Gé + Tivicay® or TDF/XTC Gé + Isentress® QD 1200 mg when available) during 16 weeks BI between W16 and W96: if pVL viral load &lt;500 cp/mL at W4 and &lt;50 cp/mL at W12, participants will start the 2-DR regimen TDF or TAF / XTC (TDF/XTC Gé or Descovy®) at W16, until W96.
(Descovy® : provided that it is available in France), (XTC = FTC or 3TC)
Immediate Bitherapy (BI) strategy Dolutegravir (DTG, Tivicay® 50 mg QD) plus lamivudine (3TC, 300 mg QD) between D0 and W96.
Antiretroviral drugs will be prescribed in the context of standard of care.</description>
    <arm_group_label>Strategy Immediate BI</arm_group_label>
    <arm_group_label>Strategy TRI-BI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV-1 infection (positive HIV-1 serology or plasma viral load)

          -  Age ≥ 18 years

          -  Therapeutic antiretroviral treatment-naive participant (history of prophylaxy is
             accepted)

          -  CD4 cells count &gt; 300 cells/mm3 at screening visit

          -  HIV-1-RNA plasma viral load &lt;50 000 copies/mL at screening visit

          -  Full susceptibility to trial drugs (NRTI, INI) at screening visit

          -  eGFR (epidermal growth factor receptor) &gt; 60 mL /min (MDRD)

          -  AST (aspartate aminotransferase), ALT(alanine transaminase) &lt; 3x norm

          -  Absence of any AIDS-defining event and/or opportunistic infection

          -  Possible contact by phone and/or email in order to be informed in case of detectable
             HIV plasma viral load

          -  Negative urinary pregnancy test at screening visit for women of childbearing age

          -  Written and informed consent signed

          -  For French participants only: subject enrolled in or a beneficiary of a Social
             Security programme (including State Medical Aid (AME), only if Ethic Committee
             approves it)

        Exclusion Criteria:

          -  HIV-2 co-infection

          -  Hepatitis B Virus infection (positive HBs antigen)

          -  Any comorbidity potentially related to a life expectancy below 12 months

          -  Any condition (use of alcohol, drugs, etc.) judged by the investigator to possibly
             interfere with trial protocol compliance, adherence and/or trial treatment tolerance

          -  Pregnant women or breastfeeding women

          -  Women of childbearing age that do not want to use an effective method of contraception

          -  Participant under justice protection

          -  Galactose/lactose intolerance, Lapp lactase deficiency or glucose/galactose
             malabsorption (known or documented)

          -  Participation to another clinical trial evaluating a new treatment/therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>MARCHAND Lucie</last_name>
    <phone>+331 53 94 80 92</phone>
    <email>lucie.marchand@anrs.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>BENIGUEL Lydie</last_name>
    <phone>+331 42 16 42 68</phone>
    <email>lbeniguel@iplesp.upmc.fr</email>
  </overall_contact_backup>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

